0000899243-23-006742.txt : 20230302 0000899243-23-006742.hdr.sgml : 20230302 20230302162233 ACCESSION NUMBER: 0000899243-23-006742 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brady Todd C CENTRAL INDEX KEY: 0001579179 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36332 FILM NUMBER: 23699292 MAIL ADDRESS: STREET 1: C/O EVOKE PHARMA, INC. STREET 2: 505 LOMAS SANTA FE DRIVE CITY: SOLANA BEACH STATE: CA ZIP: 92075 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc. CENTRAL INDEX KEY: 0001341235 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 781-761-4904 MAIL ADDRESS: STREET 1: 131 HARTWELL AVENUE STREET 2: SUITE 320 CITY: LEXINGTON STATE: MA ZIP: 02421 FORMER COMPANY: FORMER CONFORMED NAME: Aldexa Therapeutics, Inc. DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Neuron Systems Inc DATE OF NAME CHANGE: 20051012 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-28 0 0001341235 Aldeyra Therapeutics, Inc. ALDX 0001579179 Brady Todd C C/O ALDEYRA THERAPEUTICS, INC. 131 HARTWELL AVENUE LEXINGTON MA 02421 1 1 0 0 President and CEO Common Stock 2023-02-28 4 A 0 238750 0.00 A 1455285 D Stock Option (right to buy) 6.76 2023-02-28 4 A 0 250000 0.00 A 2033-02-27 Common Stock 250000 250000 D Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2023, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2023. /s/ Todd C. Brady 2023-03-02